<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-08-26T13:36:10Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/B517DD58-55F5-4E93-A3B7-195C505A81B9" ns1:id="B517DD58-55F5-4E93-A3B7-195C505A81B9"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/2C6DB08F-9C9D-4F03-AB0B-B1F7F38BC509" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/1F371898-6A77-4EA9-BEBF-EE9D8AFC18CF" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/1F371898-6A77-4EA9-BEBF-EE9D8AFC18CF" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/EDEA7753-AA07-46BF-A7D0-3D75650FC677" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2016-01-31T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/FB525DB5-4365-4E04-B21C-3A12B9DC81D2" ns1:rel="FUND" ns1:start="2014-11-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">131789</ns2:identifier></ns2:identifiers><ns2:title>Novel macrocyclic lactone compounds for crop and livestock protection</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>BEIS-Funded Programmes</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Worldwide, &amp;pound;100s of billions of crops and livestock are lost annually to pests and disease. Population growth and global improvements in standards of living mean that even more productivity must be gained from limited arable land. Unfortunately, some existing crop and livestock protection agents are losing effectiveness due to pest resistance and fewer novel agents are entering the market. Macrocyclic lactone compounds represent over a &amp;pound;1 billion annual market share, but existing products have significant shortcomings. Acidophil’s innovation, to be evaluated in this early stage feasibility study, consists of combining synthetic biology and chemistry to generate novel and improved versions of these compounds addressing the shortcomings of existing products.</ns2:abstractText></ns2:project>